It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese persons could be the result of altered circulating levels of adipokines, polypeptide hormones with proand anti-inflammatory properties secreted by adipose tissue. We investigated whether circulating levels of leptin, total adiponectin, and high molecular weight adiponectin are associated with subse-quent MM risk among 174 MM patients and 348 controls within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Inverse associations with MM were observed for total adiponectin (highest quartile vs lowest: odds ratio ‫؍‬ 0.49; 95% CI ‫؍‬ 0.26-0.93, P trend ‫؍‬ .03) and high molecular weight adiponectin (0.44; 0.23-0.85, P trend ‫؍‬ .01). These associations remained after restricting to MM patients diagnosed ϳ 8 years or more after blood collection. Leptin levels were not associated with MM risk. The results of this study, to our knowledge the first prospective investigation of circulating adipokines and MM, suggest that adiponectin may play an important role in obesity-related myelomagenesis. (Blood. 2012;120(22):4418-4420)
Introduction
Multiple myeloma (MM) is a fatal plasma cell malignancy that will account for ϳ 21 700 new cancer diagnoses in the United States in 2012. 1 Recent studies have shown that MM is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). 2 Established MM risk factors include older age, male sex, African ancestry, family history of MM or MGUS, and severe immune dysregulation. 3, 4 Obesity has also been associated with an increased risk of MGUS and MM, 5, 6 although the specific biologic mechanisms have yet to be elucidated. Alterations in circulating levels of adipokines, polypeptide hormones secreted by adipose tissue, have been proposed as a potential mechanism through which obesity contributes to myelomagenesis. The most abundant adipokine, adiponectin, is mainly produced by visceral adipose tissue 7 ; it has important anti-inflammatory and insulinsensitizing properties, and circulating levels are negatively correlated with obesity. [7] [8] [9] The ratio of the oligomeric forms of adiponectin may affect insulin sensitivity, with higher concentrations of high molecular weight (HMW) adiponectin protecting against insulin resistance. 7,10 Circulating levels of leptin, which is also produced mainly by adipocytes and has proinflammatory properties, are positively correlated with amount of body fat. 7, 10 In a recent case-control study, including 73 MM patients and 73 controls, 11 MM was inversely associated with serum levels of adiponectin and was not associated with leptin. To our knowledge, these associations have not been investigated prospectively.
To determine whether prediagnostic circulating levels of leptin, total adiponectin, and HMW adiponectin are associated with future risk of MM, we conducted a nested case-control study in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Methods
Methods for enrollment and specimen collection in the PLCO Cancer Screening Trial have been described. 12 Briefly, between 1993 and 2001, ϳ 155 000 persons 55-74 years of age were enrolled in the study from 10 US cities. Screening-arm participants provided nonfasting blood samples that were processed and frozen within 2 hours of collection and stored at Ϫ70°C. The trial was approved by institutional review boards at the National Cancer Institute and the 10 study centers, and all participants provided written informed consent in accordance with the Declaration of Helsinki.
After excluding participants with a history of cancer (other than nonmelanoma skin cancer) at baseline and those with a prior incident diagnosis of a lymphoid malignancy, we identified 174 patients with an incident diagnosis of MM (ICD-O-2-M 9732) on or before June 29, 2010 that had available prediagnostic heparin plasma (collected Ͼ 1 year before diagnosis). Two controls were individually matched to each MM patient on age at baseline (5-year categories), sex, race, date of phlebotomy (3-month categories), time of day of phlebotomy (AM, PM), and study year of specimen collection.
Plasma concentrations of leptin, total adiponectin, and HMW adiponectin were measured in duplicate by ELISA with reagents purchased from R&D Systems. Samples from MM patients and their matched controls were analyzed consecutively in the same batch, and blinded quality control replicates were included in each batch. The overall coefficients of variation for total adiponectin, HMW adiponectin, and leptin were 2.7%, 4.7%, and 8.5%, respectively. All measurements were above the lower limits of detection of 3.9 ng/mL for total and HMW adiponectin and 15.6 pg/mL for leptin.
We used a t test to assess differences in log-transformed levels of each analyte between MM patients and controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression models with subjects assigned to quartiles of each analyte (averaged Submitted June 21, 2012; accepted September 10, 2012. Prepublished online as Blood First Edition paper, September 24, 2012; DOI 10.1182/blood-2012-06-438606.
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Results and discussion
The distributions of matching factors among MM patients and controls were the same (Table 1) . BMI, which is associated with MM in the PLCO Cancer Screening Trial, 13 was slightly higher among selected MM patients than among controls. MM patients had lower levels of total and HMW adiponectin than did controls (P ϭ .001 and .003, respectively). BMI was positively correlated with leptin and negatively correlated with total and HMW adiponectin (Spearman correlation coefficients for leptin, total adiponectin, and HMW adiponectin were 0.52, Ϫ0.26, and Ϫ0.25, respectively, among controls and 0.59, Ϫ0.24, and Ϫ0.27 among MM patients).
As shown in Figure 1 , we observed inverse associations between MM risk and plasma levels of total adiponectin (highest quartile vs lowest: OR ϭ 0.49; 95% CI ϭ 0.26-0.93; P trend ϭ .03) and HMW adiponectin (OR ϭ 0.44; 95% CI ϭ 0.23-0.85; P trend ϭ .01). No consistent patterns of association were observed for leptin. When the top quartile was subdivided using the within-category median, stronger associations were observed for those subjects with the highest levels of total adiponectin (OR ϭ 0.33; 95% CI ϭ 0.14-0.79) and HMW adiponectin (OR ϭ 0.32; 95% CI ϭ 0.14-0.75). These associations remained after restricting the analysis to MM patients diagnosed Ͼ 7.91 years after blood collection and their matched controls (supplemental Table 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Findings were similar among men and women (eg, total adiponectin: OR continuous ϭ 0.71 for men and 0.79 for women; supplemental Table 2 ). Risk estimates were essentially unchanged after adjustment for BMI, when leptin was included as a covariate in the analyses of total and HMW adiponectin, and after restricting to non-Hispanic whites (not shown).
We observed a modest association between BMI and MM risk in this analysis (ORs per 5 kg/m 2 increase ϭ 1.14; 95% CI ϭ 0.94-1.39), the magnitude of which is consistent with the summary risk estimate from a meta-analysis of prospective studies of MM. 5 When we adjusted for adiponectin, which was negatively correlated with BMI, this association was attenuated by ϳ 40% (ORs per 5 kg/m 2 increase of 1.08 and 1.09 after adjusting for HMW and total adiponectin, respectively).
Our study, to our knowledge the first prospective investigation of circulating adipokines and MM, shows a clear inverse relationship between total and HMW adiponectin levels and subsequent risk of MM, even among MM patients diagnosed approximately Ն 8 years after blood collection. These results suggest that adiponectin may play a role in the underlying biologic mechanisms linking obesity to myelomagenesis. Although the mechanisms are not fully understood, adiponectin may prevent MM development by suppressing production of proinflammatory cytokines, such as IL-6 and TNF, and inhibiting NF-B activation while inducing other anti-inflammatory cytokines, such as IL-10 and IL-1RA, thereby affecting transduction pathways associated with survival and proliferation of malignant plasma cells. 10, [14] [15] [16] Insulin and IGF-1 also promote myeloma cell growth and migration, 14, [17] [18] [19] and GSD indicates geometric standard deviation. *P ϭ .001 and .003 for total and HMW adiponectin, respectively. To account for the matched design, we used a bootstrap procedure that resampled each case and the 2 matched controls as the independent unit and computed the t test statistic for each bootstrap dataset for the log-transformed value of each analyte and for BMI. P values are based on the bootstrap distribution function with 5000 bootstrap replications.
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